Literature DB >> 12717407

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.

Maria Buti, Auristela Valdés, Francisco Sánchez-Avila, Rafael Esteban, Yoav Lurie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12717407     DOI： 10.1053/jhep.2003.50107

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  5 in total

1.  Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

Authors:  M Milan; S Boninsegna; L Scribano; S Lobello; S Fagiuoli; P Fabris; A Buda; D Martines
Journal:  Infection       Date:  2011-11-18       Impact factor: 3.553

Review 2.  Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

Authors:  Brian L Pearlman
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  Management of chronic hepatitis C: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

Review 4.  Antiviral therapy for chronic hepatitis C: past, present, and future.

Authors:  Norio Hayashi; Tetsuo Takehara
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 6.772

5.  Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis.

Authors:  Seyed Moayed Alavian; Seyed Vahid Tabatabaei; Bita Behnava; Nastaran Mahboobi
Journal:  Hepat Mon       Date:  2011-08       Impact factor: 0.660
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.